Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region

Annunziata Dattola; Nicoletta Bernardini; Giacomo Caldarola; Rosa Coppola; Clara De Simone; Domenico Giordano; Alessandro Giunta; Gaia Moretta; Gianluca Pagnanelli; Vincenzo Panasiti; Severino Persechino; Concetta Potenza; Federica Trovato; Arianna Zangrilli; Luca Bianchi; Giovanni Pellacani; Ketty Peris; Antonio Giovanni Richetta

doi:10.5826/dpc.1403a166

Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region

Authors

Annunziata Dattola Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy
Nicoletta Bernardini Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome - Polo Pontino, ASL Latina
Giacomo Caldarola Section of Dermatology, Department of Translational Medicine and Surgery, Catholic University of the S. Heart; Rome, Italy
Rosa Coppola Fondazione Policlinico Universitario Campus Bio Medico, Rome Italy
Clara De Simone Section of Dermatology, Department of Translational Medicine and Surgery, Catholic University of the S. Heart; Rome, Italy
Domenico Giordano Department of Neurosciences, Mental Health and Sensory Organs, “Sapienza” University of Rome, Rome, Italy
Alessandro Giunta Dermatology Unit, University of Rome “Tor Vergata”, Rome, Italy
Gaia Moretta Department of Dermatology, Istituto Dermopatico dell'Immacolata IDI IRCCS, Rome. Italy
Gianluca Pagnanelli Department of Dermatology, Istituto Dermopatico dell'Immacolata IDI IRCCS, Rome. Italy
Vincenzo Panasiti Fondazione Policlinico Universitario Campus Bio Medico, Rome Italy
Severino Persechino Department of Neurosciences, Mental Health and Sensory Organs, “Sapienza” University of Rome, Rome, Italy
Concetta Potenza Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome - Polo Pontino, ASL Latina
Federica Trovato Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy
Arianna Zangrilli Dermatology Unit, University of Rome “Tor Vergata”, Rome, Italy
Luca Bianchi Dermatology Unit, University of Rome “Tor Vergata”, Rome, Italy
Giovanni Pellacani Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy
Ketty Peris Section of Dermatology, Department of Translational Medicine and Surgery, Catholic University of the S. Heart; Rome, Italy
Antonio Giovanni Richetta Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy

Keywords:

psoriasis, interleukin 17, ixekizumab, real life, elderly, effectiveness

Abstract

Introduction: This was an observational, retrospective, multicenter study, enrolling elderly patients (>65 years old) treated with ixekizumab with a diagnosis of psoriasis (PsO) and/or psoriatic arthritis (PsA) during the period 2020 to 2023.
Objectives: We sought to investigate the efficacy of ixekizumab in elderly patients in the treatment of moderate to severe psoriasis.
Methods: We included 73 patients with psoriasis (32.9%), psoriatic arthritis (1.4%) and both of them (PsO-PsA 65.8%), attending the outpatient clinics of seven Italian referral center for psoriasis in Lazio region: Policlinico Umberto I Università Roma La Sapienza, Sant’Andrea Università di Roma La Sapienza, Polo Pontino Università Roma La Sapienza, Fondazione Policlinico Universitario A. Gemelli, Università Campus Biomedico Roma, Istituto Dermopatico dell’Immacolata, and Policlinico Tor Vergata. We collected data related to the characteristics of the patients (age, sex, body mass index) and of the disease (age at onset, duration of psoriasis, previous treatments). The severity of psoriasis was measured with the Psoriasis Area and Severity Index (PASI) score at baseline and after 16, 24, 52, 104 and 156 weeks of treatment.
Results: PASI90 was achieved by all the patients in week 16 and remained stable until the end of the study. PASI100 has been achieved by 55.1% of patients at weeks 16 and by 81.3% at week 104. A statistically significant difference has been highlighted between baseline and all the other time points (p<0.0001) for PASI score. A similar trend was observed for VAS score and DLQI score.
Conclusions: Ixekizumab was effective and with a good safety profile in psoriatic patients over 65 years. No significant adverse events were reported.

References

New insights into the pathogenesis of cutaneous autoimmune disorders. Chiricozzi A, Zhang S, Dattola A, Cannizzaro MV, Gabellini M, Chimenti S, Nistico SP.J Biol Regul Homeost Agents. 2012 Apr-Jun;26(2):165-70.

Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Vena GA, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, Giannetti A, Girolomoni G, Lotti T, Martini P, Mazzaglia G, Peserico A, Puglisi Guerra A, Sini G, Cassano N, Cricelli C. Eur J Dermatol. 2010 Sep-Oct;20(5):593-8. doi: 10.1684/ejd.2010.1017. Epub 2010 Jul 7. PMID: 20605768

Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN, van de Kerkhof P, Ståhle M, Nestle FO, Girolomoni G, Krueger JG. J Invest Dermatol. 2010 Jul;130(7):1785-96. doi: 10.1038/jid.2010.103. Epub 2010 May 6. PMID: 20445552

Psoriasis, the liver, and the gastrointestinal tract. Gisondi P, Del Giglio M, Cozzi A, Girolomoni G. Dermatol Ther. 2010 Mar-Apr;23(2):155-9. doi: 10.1111/j.1529-8019.2010.01310.x.PMID: 20415823

Role of Th17 in the pathogenesis of cutaneous inflammatory diseases. Chiricozzi A, Zhang S, Dattola A, Gabellini M, Chimenti S, Nistico SP.J Biol Regul Homeost Agents. 2012 Jul-Sep;26(3):313-8.

Emerging role of anti-IL23 in the treatment of psoriasis: When humanized is very promising.

Dattola A, Silvestri M, Tamburi F, Amoruso GF, Bennardo L, Nisticò SP.Dermatol Ther. 2020 Nov;33(6):e14504. doi: 10.1111/dth.14504. Epub 2020 Nov 10.PMID: 33141505

Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology.

Lanna C, Lambiase S, Gaeta Shumak R, Borselli C, Cosio T, Dattola A, Bianchi L, Campione E.Expert Rev Clin Pharmacol. 2022 Oct;15(10):1209-1224. doi: 10.1080/17512433.2022.2130758. Epub 2022 Oct 8.

Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Brembilla NC, Boehncke WH. Front Immunol. 2023 May 22;14:1186455. doi: 10.3389/fimmu.2023.1186455. eCollection 2023.

PMID: 37283755

Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, Shrom D, Amato D, Okubo Y, Reich K. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1686-1692. doi: 10.1111/jdv.14237. Epub 2017 Apr 26. PMID: 28322474. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).

Megna M, Cinelli E, Balato A et al. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period. J Eur Acad Dermatol Venereol 2020; 34: e152–3.

Efficacy and safety of infliximab in psoriatic patients over the age of 65. Chiricozzi A, Pavlidis A, Dattola A, Bianchi L, Chimenti MS, Fida M, Saraceno R.Expert Opin Drug Saf. 2016 Nov;15(11):1459-1462. doi: 10.1080/14740338.2016.1226279. Epub 2016 Aug 31.

Piaserico S, Conti A, Lo Console F et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol 2014; 94: 293–7.

Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M.Clin Exp Dermatol. 2022 Mar;47(3):561-567. doi: 10.1111/ced.14979. Epub 2021 Nov 17.Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.

Esposito M, Giunta A, Mazzotta A et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology 2012; 225: 312–19.

Megna M, Camela E, Cinelli E, Fabbrocini G. Real-life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol 2020; 45: 848–52.

Ko€rber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging 2018; 35: 135–44.

Eli Lilly & Co. Taltz (ixekizumab). Summary of Product Characteristics. Data on File. 2016.